Publication date: Dec 20, 2024
Little is known about how symptoms or symptom clusters of Post-COVID Conditions (PCC) impact an individual’s return to pre-COVID health. We used four state-level COVID-19 case reporting systems and patient-reported survey data to identify patients with PCC and associations with an individual’s return to pre-COVID health after laboratory-confirmed SARS-CoV-2 infection. Participants had a positive SARS-CoV-2 test between March-December 2020. Weighted regression models were used to 1) estimate prevalence of PCC; 2) identify risk factors associated with developing PCC; and 3) examine associations between PCC symptom clusters and return to pre-COVID health. Factor analysis was used to statistically identify post-COVID symptom clusters. Prevalence of PCC in this population-based sample was 29.9% for persons with SARS-CoV-2 infection, during the pre-delta variant period (March-December 2020); 77.2% of persons experiencing PCC had not returned to pre-COVID health within 8-60 weeks after infection. Female sex, acute COVID-19 illness severity, and number of pre-existing comorbidities were significant risk factors associated with PCC. Myalgic encephalomyelitis/chronic fatigue syndrome-like symptoms, upper-respiratory symptoms, and gastrointestinal symptoms were significantly associated with not returning to pre-COVID health. Understanding PCC symptom clustering may provide insight into pathophysiology, severity of PCC, and management for patients who have not returned to their usual state of health after SARS-CoV-2 infection. Tracking PCC can help measure the impact of COVID-19 vaccination and acute COVID-19-specific treatments on reducing PCC in the US.
Concepts | Keywords |
---|---|
Pathophysiology | Long COVID |
Pcc | Post-COVID condition |
Vaccination | prevalence |
risk factors | |
SARS-CoV-2 | |
symptom clusters |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Post-COVID Condition |
disease | MESH | Symptom Clusters |
drug | DRUGBANK | Factor IX Complex (Human) |
disease | MESH | COVID-19 |
pathway | REACTOME | SARS-CoV-2 Infection |
disease | MESH | infection |
disease | MESH | Myalgic encephalomyelitis |
disease | IDO | symptom |
disease | MESH | sequelae |